Avesthagen Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Avesthagen Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013103
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Avesthagen Ltd (Avesthagen) is a life science company that offers preventive personalized healthcare solutions. The company offers bio-nutrition, bio-agriculture and bio-pharmaceutical products. Its bio-nutrition products include validated bio-actives from Indian medicinal plants for prevention or treatment of degenerative conditions such as diabetes, obesity, CVD and bone health. Avesthagen’s bio-agriculture products provide biotic & abiotic stress resistance, oil enhancement and developing functional foods from plants. The company also provides engineering and development, validation, strategic positioning and marketing services. It sells its products through a network of distributors in India and abroad markets. Avesthagen is headquartered in Bangalore, Karnataka, India.

Avesthagen Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Avesthagen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Avesthagen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Avesthagen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Avesthagen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Avesthagen Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Avesthagen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Avesthagen Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Avesthagen Plans To Raise US$126 Million In Financing 11
Private Equity 12
Avesthagen Plans to Raise USD126 Million in Private Equity 12
Avesthagen Plans To Raise US$60 Million From Equity Partner Fund 13
Partnerships 14
Avesthagen Enters Into Co-Development Agreement With CosmosID 14
Avesthagen Enters Into Co-Development Agreement With KUTLO-NITT 15
Acquisition 16
SAVA Medica Acquire 50% Stake In Dhanvantari Botanicals From Avesthagen 16
Avesthagen Ltd – Key Competitors 17
Avesthagen Ltd – Key Employees 18
Avesthagen Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Joint Venture 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Avesthagen Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Avesthagen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Avesthagen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Avesthagen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Avesthagen Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Avesthagen Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Avesthagen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Avesthagen Plans To Raise US$126 Million In Financing 11
Avesthagen Plans to Raise USD126 Million in Private Equity 12
Avesthagen Plans To Raise US$60 Million From Equity Partner Fund 13
Avesthagen Enters Into Co-Development Agreement With CosmosID 14
Avesthagen Enters Into Co-Development Agreement With KUTLO-NITT 15
SAVA Medica Acquire 50% Stake In Dhanvantari Botanicals From Avesthagen 16
Avesthagen Ltd, Key Competitors 17
Avesthagen Ltd, Key Employees 18
Avesthagen Ltd, Subsidiaries 19
Avesthagen Ltd, Joint Venture 19

★海外企業調査レポート[Avesthagen Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • UMN Pharma Inc (4585):企業の財務・戦略的SWOT分析
    Summary UMN Pharma Inc (UMN Pharma) is a biopharmaceutical company that manufactures therapeutic for muscular dystrophy, diabetes and influenza. The company’s products include UMN-0501, UMN-0502, UMN-2003, UMN-0901 and UMN-2002, among others. Its UMN-0502 is a seasonal influenza vaccine. UMN Pharma’ …
  • Avanti Energy Inc (AVN):企業の財務・戦略的SWOT分析
    Summary Avanti Energy Inc (Avanti Energy), formerly known as Overlord Capital Ltd is an oil and gas exploration and production company. The company acquires, explores, and develops gas reserves in Central Italy. It re-develops the existing oil and gas reserves. Avanti Energy owns the Colle Santo gas …
  • Aradigm Corp (ARDM):企業の財務・戦略的SWOT分析
    Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sunsweet Growers Inc.:企業の戦略・SWOT・財務情報
    Sunsweet Growers Inc. - Strategy, SWOT and Corporate Finance Report Summary Sunsweet Growers Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Mapfre SA (MAP):企業の財務・戦略的SWOT分析
    Mapfre SA (MAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Bone Solutions Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bone Solutions Inc (BSI) is a medical device company that provides orthobiologics technology solutions. The company also develops magnesium oxide based technologies for multitude of orthopedic applications. It provides osteocrete bone graft substitute that offers adhere ligaments and tendons …
  • Quadrise Fuels International Plc (QFI)-石油・ガス分野:企業M&A・提携分析
    Summary Quadrise Fuels International Plc (QFI), formerly Zareba Plc, is an oil-in-water emulsified fuel developer that manufactures and markets MSAR (Multiphase Superfine Atomised Residue), an emulsion fuel as a low cost substitute for conventional heavy fuel oil (HFO) for use in power generation pl …
  • Aduro BioTech Inc (ADRO):製薬・医療:M&Aディール及び事業提携情報
    Summary Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sti …
  • Oberoi Realty Limited:企業の戦略・SWOT・財務情報
    Oberoi Realty Limited - Strategy, SWOT and Corporate Finance Report Summary Oberoi Realty Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Laboratorios Liomont SA de CV:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratorios Liomont SA de CV (Liomont) is a pharmaceutical company that develops medication products. The company offers prescription medication products, biotech products and over the counter products. It provides drugs in various therapeutic areas including analgesics, antiparasitic, anti …
  • GREE, Inc. (3632):企業の財務・戦略的SWOT分析
    GREE, Inc. (3632) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • China Digital Culture (Group) Ltd (8175):企業の財務・戦略的SWOT分析
    China Digital Culture (Group) Ltd (8175) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Itausa – Investimentos Itau SA (ITSA4):企業の財務・戦略的SWOT分析
    Itausa - Investimentos Itau SA (ITSA4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • TenCate Advanced Armour:企業の戦略・SWOT・財務分析
    TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report Summary TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Kane Biotech Inc (KNE):企業の財務・戦略的SWOT分析
    Summary Kane Biotech Inc (Kane Biotech) is a biotechnology company which focuses on research, development and commercialization of novel products that prevent and remove biofilm related infections in humans and animals. The company’s products include StrixNB and Vetradent water additive, oral spray, …
  • Walgreens Boots Alliance, Inc.:企業の戦略・SWOT・財務情報
    Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Keikyu Corporation:企業の戦略・SWOT・財務情報
    Keikyu Corporation - Strategy, SWOT and Corporate Finance Report Summary Keikyu Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Bet Shemesh Engines Holdings (1997) Ltd:企業の戦略・SWOT・財務分析
    Bet Shemesh Engines Holdings (1997) Ltd - Strategy, SWOT and Corporate Finance Report Summary Bet Shemesh Engines Holdings (1997) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析
    Summary Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, SKIL (Sareum Kinase Inhib …
  • PIQUR Therapeutics AG:製薬・医療:M&Aディール及び事業提携情報
    Summary PIQUR Therapeutics AG (PIQUR) is a developer of anti-cancer drugs. The company develops innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibitior for the treatment of cancer and inflammatory diseases. Its pipeline products comprise PQR-309, PQR-620, PQR-530, PQR …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆